Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Oral desmopressin evaluated in bed-wetting children

Oct. 13, 1997

Vanguard licenses VML-252 to Sankyo

Oct. 10, 1997

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Oct. 10, 1997

Unique profile described for Glaxo Wellcome's 5alpha-reductase inhibitor

Oct. 8, 1997

Empi's new incontinence device approved by FDA; worldwide launch slated for January

Oct. 7, 1997

Development of YM-46303 stopped

Oct. 2, 1997

Interstim approved for marketing in U.S.

Oct. 1, 1997

Alza to market IVAX urology products in U.S., Canada

Sep. 30, 1997

Bosentan evaluated in humans for preventing ciclosporin nephrotoxicity

Sep. 29, 1997

Synaptic focuses on dihydropyrimidinones for BPH

Sep. 29, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.